nach oben

Tumor Biology

Erschienen in:

02.12.2015 | Original Article

The expression levels of the sirtuins in patients with BCC

verfasst von: Metin Temel, Mustafa Nihat Koç, Saffet Ulutaş, Bülent Göğebakan

Erschienen in: Tumor Biology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Basal cell carcinoma (BCC) is the most common tumor in humans. Reduced expression of sirtuins interferes with DNA repair, which may cause mutations and genomic instability, and eventually leads to tumor development. In the present study, we investigate the expression levels of SIRT genes in non-tumoral and tumor tissues of patients with BCC. A total of 27 patients (16 males, 11 females) with BCC were included in the study; the mean age was 65.40 ± 10.74 years and mean follow-up was 2.5 ± 0.5 years. There were multiple synchronous lesions in six patients, and the remaining 21 patients had a single lesion. Tumor and non-tumoral tissue samples were collected from all patients, and mRNA expression levels of SIRT1–7 (Sirt1.1, Sirt1.2, Sirt2, Sirt3, Sirt4, Sirt5, Sirt6, and Sirt7) were examined by real-time PCR. The results showed that expressions of SIRT1.1, SIRT1.2, SIRT4, SIRT5, SIRT6, and SIRT7 mRNAs were unchanged in tumor tissues of BCC patients compared with non-tumoral tissue samples. Importantly, the expressions of SIRT2 and SIRT3 mRNAs were significantly reduced in tumor tissue samples from BCC patients compared with non-tumoral tissues (P = 0.02 and P = 0.03, respectively). In light of the previous reports that have demonstrated a link between SIRT proteins and cancer, our findings suggest that SIRT2 and SIRT3 may plan important roles in BCC pathogenesis and could be candidate prognostic biomarkers for BCC.

Savoia P, Deboli T, Previgliano A, Broganelli P. Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma. Int J Mol Sci. 2015;16(10):23300–17. doi:10.3390/ijms161023300.CrossRefPubMedPubMedCentral

Deng M, Marsch AF, Petronic-Rosic V. Basal cell carcinoma. Part 1: basal cell carcinoma has come of age. Skinmed. 2015;13(3):206–13. quiz 14.PubMed

Chu SW, Biswas A. Basal cell carcinomas showing histological features generally associated with cutaneous adnexal neoplasms. J Cutan Pathol. 2015. doi:10.1111/cup.12577.

Gualdi G, Monari P, Apalla Z, Lallas A. Surgical treatment of basal cell carcinoma and squamous cell carcinoma. G Ital Dermatol Venereol. 2015;150(4):435–47.PubMed

Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep. 2015;7:53. doi:10.12703/P7-53.CrossRefPubMedPubMedCentral

Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2000;403(6771):795–800. doi:10.1038/35001622.CrossRefPubMed

Houtkooper RH, Pirinen E, Auwerx J. Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol. 2012;13(4):225–38. doi:10.1038/nrm3293.CrossRefPubMedPubMedCentral

Hallows WC, Albaugh BN, Denu JM. Where in the cell is SIRT3?—functional localization of an NAD+-dependent protein deacetylase. Biochem J. 2008;411(2):e11–3. doi:10.1042/BJ20080336.CrossRefPubMedPubMedCentral

Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16(10):4623–35. doi:10.1091/mbc.E05-01-0033.CrossRefPubMedPubMedCentral

10.

Longo VD, Kennedy BK. Sirtuins in aging and age-related disease. Cell. 2006;126(2):257–68. doi:10.1016/j.cell.2006.07.002.CrossRefPubMed

11.

Voelter-Mahlknecht S, Mahlknecht U. Cloning, chromosomal characterization and mapping of the NAD-dependent histone deacetylases gene sirtuin 1. Int J Mol Med. 2006;17(1):59–67.PubMed

12.

Hida Y, Kubo Y, Murao K, Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen’s disease. Arch Dermatol Res. 2007;299(2):103–6. doi:10.1007/s00403-006-0725-6.CrossRefPubMed

13.

Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007;26(37):5489–504. doi:10.1038/sj.onc.1210616.CrossRefPubMed

14.

Haigis MC, Guarente LP. Mammalian sirtuins—emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006;20(21):2913–21. doi:10.1101/gad.1467506.CrossRefPubMed

15.

Michan S, Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007;404(1):1–13. doi:10.1042/BJ20070140.CrossRefPubMedPubMedCentral

16.

Poulose N, Raju R. Sirtuin regulation in aging and injury. Biochim Biophys Acta. 2015;1852(11):2442–55. doi:10.1016/j.bbadis.2015.08.017.CrossRefPubMedPubMedCentral

17.

Matsushima S, Sadoshima J. The role of sirtuins in cardiac disease. American journal of physiology Heart and circulatory physiology. 2015:ajpheart 00053 2015. doi:10.1152/ajpheart.00053.2015.

18.

Miyo M, Yamamoto H, Konno M, Colvin H, Nishida N, Koseki J, et al. Tumour-suppressive function of SIRT4 in human colorectal cancer. Br J Cancer. 2015;113(3):492–9. doi:10.1038/bjc.2015.226.CrossRefPubMedPubMedCentral

19.

Sayd S, Thirant C, El-Habr EA, Lipecka J, Dubois LG, Bogeas A, et al. Sirtuin-2 activity is required for glioma stem cell proliferation arrest but not necrosis induced by resveratrol. Stem Cell Rev. 2014;10(1):103–13. doi:10.1007/s12015-013-9465-0.CrossRefPubMed

20.

Abdelmohsen K, Pullmann Jr R, Lal A, Kim HH, Galban S, Yang X, et al. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol Cell. 2007;25(4):543–57. doi:10.1016/j.molcel.2007.01.011.CrossRefPubMedPubMedCentral

21.

Murayama A, Ohmori K, Fujimura A, Minami H, Yasuzawa-Tanaka K, Kuroda T, et al. Epigenetic control of rDNA loci in response to intracellular energy status. Cell. 2008;133(4):627–39. doi:10.1016/j.cell.2008.03.030.CrossRefPubMed

22.

Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 2001;107(2):137–48.CrossRefPubMed

23.

Rajamohan SB, Pillai VB, Gupta M, Sundaresan NR, Birukov KG, Samant S, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol. 2009;29(15):4116–29. doi:10.1128/MCB.00121-09.CrossRefPubMedPubMedCentral

24.

Yamamori T, DeRicco J, Naqvi A, Hoffman TA, Mattagajasingh I, Kasuno K, et al. SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 2010;38(3):832–45. doi:10.1093/nar/gkp1039.CrossRefPubMed

25.

Noguchi A, Li X, Kubota A, Kikuchi K, Kameda Y, Zheng H, et al. SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(3):385–92. doi:10.1016/j.oooo.2012.12.013.CrossRefPubMed

26.

Wilking MJ, Singh C, Nihal M, Zhong W, Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys. 2014;563:94–100. doi:10.1016/j.abb.2014.04.001.CrossRefPubMedPubMedCentral

27.

Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. 2006;124(2):315–29. doi:10.1016/j.cell.2005.11.044.CrossRefPubMed

28.

Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006;20(9):1075–80. doi:10.1101/gad.1399706.CrossRefPubMedPubMedCentral

29.

De Nigris F, Cerutti J, Morelli C, Califano D, Chiariotti L, Viglietto G, et al. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br J Cancer. 2002;87(12):1479. doi:10.1038/sj.bjc.6600636.CrossRefPubMedPubMedCentral

30.

Frye R. “SIRT8” expressed in thyroid cancer is actually SIRT7. Br J Cancer. 2002;87(12):1479. doi:10.1038/sj.bjc.6600635.CrossRefPubMedPubMedCentral

31.

Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer. 2006;95(8):1056–61. doi:10.1038/sj.bjc.6603384.CrossRefPubMedPubMedCentral

32.

Movahedi Naini S, Sheridan AM, Force T, Shah JV, Bonventre JV. Group IVA cytosolic phospholipase A2 regulates the G2-to-M transition by modulating the activity of tumor suppressor SIRT2. Mol Cell Biol. 2015;35(21):3768–84. doi:10.1128/MCB.00184-15.CrossRefPubMedPubMedCentral

33.

Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev. 2000;14(9):1021–6.PubMed

34.

Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci. 2003;60(9):1990–7. doi:10.1007/s00018-003-3090-z.CrossRefPubMed

35.

Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW. DNA repair, genome stability, and aging. Cell. 2005;120(4):497–512. doi:10.1016/j.cell.2005.01.028.CrossRefPubMed

36.

Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell. 2011;20(4):487–99. doi:10.1016/j.ccr.2011.09.004.CrossRefPubMedPubMedCentral

37.

Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004;6(1):1–6.CrossRefPubMedPubMedCentral

38.

Aguissa-Toure AH, Wong RP, Li G. The ING family tumor suppressors: from structure to function. Cell Mol Life Sci. 2011;68(1):45–54. doi:10.1007/s00018-010-0509-1.CrossRefPubMed

39.

Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J, et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell. 2006;23(4):607–18. doi:10.1016/j.molcel.2006.06.026.CrossRefPubMed

40.

North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003;11(2):437–44.CrossRefPubMed

41.

Rose G, Dato S, Altomare K, Bellizzi D, Garasto S, Greco V, et al. Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Exp Gerontol. 2003;38(10):1065–70.CrossRefPubMed

42.

Glatt SJ, Chayavichitsilp P, Depp C, Schork NJ, Jeste DV. Successful aging: from phenotype to genotype. Biol Psychiatry. 2007;62(4):282–93. doi:10.1016/j.biopsych.2006.09.015.CrossRefPubMed

43.

Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell. 2005;120(4):483–95. doi:10.1016/j.cell.2005.02.001.CrossRefPubMed

44.

Lombard DB, Alt FW, Cheng HL, Bunkenborg J, Streeper RS, Mostoslavsky R, et al. Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol. 2007;27(24):8807–14. doi:10.1128/MCB.01636-07.CrossRefPubMedPubMedCentral

45.

Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010;17(1):41–52. doi:10.1016/j.ccr.2009.11.023.CrossRefPubMedPubMedCentral

46.

Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell. 2011;19(3):416–28. doi:10.1016/j.ccr.2011.02.014.CrossRefPubMedPubMedCentral

47.

Bell EL, Emerling BM, Ricoult SJ, Guarente L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene. 2011;30(26):2986–96. doi:10.1038/onc.2011.37.CrossRefPubMedPubMedCentral

48.

Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A. 2002;99(21):13653–8. doi:10.1073/pnas.222538099.CrossRefPubMedPubMedCentral

49.

Schwer B, North BJ, Frye RA, Ott M, Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol. 2002;158(4):647–57. doi:10.1083/jcb.200205057.CrossRefPubMedPubMedCentral

50.

Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–5. doi:10.1038/nature08778.CrossRefPubMedPubMedCentral

51.

Qiu X, Brown K, Hirschey MD, Verdin E, Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab. 2010;12(6):662–7. doi:10.1016/j.cmet.2010.11.015.CrossRefPubMed

52.

Someya S, Yu W, Hallows WC, Xu J, Vann JM, Leeuwenburgh C, et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell. 2010;143(5):802–12. doi:10.1016/j.cell.2010.10.002.CrossRefPubMedPubMedCentral

53.

Chen IC, Chiang WF, Liu SY, Chen PF, Chiang HC. Role of SIRT3 in the regulation of redox balance during oral carcinogenesis. Mol Cancer. 2013;12:68. doi:10.1186/1476-4598-12-68.CrossRefPubMedPubMedCentral

54.

Quan Y, Wang N, Chen Q, Xu J, Cheng W, Di M et al. SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. Oncotarget. 2015.

55.

Wang L, Wang WY, Cao LP. SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1. Int J Clin Exp Med. 2015;8(4):5263–71.PubMedPubMedCentral

56.

Lesiak A, Sobolewska-Sztychny D, Majak P, Sobjanek M, Wodz K, Sygut KP, et al. Relation between sonic hedgehog pathway gene polymorphisms and basal cell carcinoma development in the Polish population. Arch Dermatol Res. 2015. doi:10.1007/s00403-015-1612-9.PubMed

57.

Morrow D, Cullen JP, Liu W, Guha S, Sweeney C, Birney YA, et al. Sonic Hedgehog induces Notch target gene expression in vascular smooth muscle cells via VEGF-A. Arterioscler Thromb Vasc Biol. 2009;29(7):1112–8. doi:10.1161/ATVBAHA.109.186890.CrossRefPubMedPubMedCentral

58.

Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11):e13984. doi:10.1371/journal.pone.0013984.CrossRefPubMedPubMedCentral

59.

He S, He C, Yuan H, Xiong S, Xiao Z, Chen L. The SIRT 3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients. Cell Physiol Biochem. 2014;34(6):2061–9. doi:10.1159/000366401.CrossRefPubMed

60.

Liu R, Fan M, Candas D, Qin L, Zhang X, Eldridge A, et al. CDK1-mediated SIRT3 activation enhances mitochondrial function and tumor radioresistance. Mol Cancer Ther. 2015;14(9):2090–102. doi:10.1158/1535-7163.MCT-15-0017.CrossRefPubMedPubMedCentral

61.

Gonzalez Herrera KN, Lee J, Haigis MC. Intersections between mitochondrial sirtuin signaling and tumor cell metabolism. Crit Rev Biochem Mol Biol. 2015;50(3):242–55. doi:10.3109/10409238.2015.1031879.CrossRefPubMed

Titel: The expression levels of the sirtuins in patients with BCC
verfasst von: Metin Temel
Mustafa Nihat Koç
Saffet Ulutaş
Bülent Göğebakan
Publikationsdatum: 02.12.2015
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 5/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-4522-8

Springer Medizin

The expression levels of the sirtuins in patients with BCC

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2016

Genetic variation in vitamin D-related genes and risk of breast cancer among women of European and East Asian descent

MicroRNA-144 mediates metabolic shift in ovarian cancer cells by directly targeting Glut1

The relationship between five non-synonymous polymorphisms within three XRCC genes and gastric cancer risk in a Han Chinese population

Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway

MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma

MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie